Near­ly a year af­ter Au­den­tes' gene ther­a­py deaths, the tri­al con­tin­ues. What hap­pened re­mains a mys­tery

Na­tal­ie Holles was five months in­to her tenure as Au­dentes CEO and work­ing to smooth out a $3 bil­lion merg­er when the world crashed in.

Holles and her team re­ceived word on the morn­ing of May 5 that, hours be­fore, a pa­tient died in a tri­al for their lead gene ther­a­py. They went in­to triage mode, alert­ing the FDA, call­ing tri­al in­ves­ti­ga­tors to be­gin to un­der­stand what hap­pened, and, the next day, writ­ing a let­ter to alert the pa­tient com­mu­ni­ty so they would be the first to know. “We want­ed to be as forth­right and trans­par­ent as pos­si­ble,” Holles told me late last month.

The brief let­ter not­ed two oth­er pa­tients al­so suf­fered se­vere re­ac­tions af­ter re­ceiv­ing a high dose of the ther­a­py and were un­der­go­ing treat­ment. One died a month and a half lat­er, at which point news of the deaths be­came pub­lic, jolt­ing an emer­gent gene ther­a­py field and rais­ing ques­tions about the safe­ty of the high dos­es Au­dentes and oth­ers were now us­ing. The third pa­tient died in Au­gust.

“It was deeply sad­den­ing,” Holles said. “But I was — we were — res­olute and de­ter­mined to un­der­stand what hap­pened and learn from it and get back on track.”

Eleven months have now passed since the first death and the ther­a­py, a po­ten­tial cure for a rare and fa­tal mus­cle-wast­ing dis­ease called X-linked my­otubu­lar my­opa­thy, is back on track, the FDA hav­ing cleared the com­pa­ny to re­sume dos­ing at a low­er lev­el. Au­dentes it­self is no more; last month, Japan­ese phar­ma gi­ant Astel­las an­nounced it had com­plet­ed work­ing out the kinks of the $3 bil­lion merg­er and had re­struc­tured and re­brand­ed the sub­sidiary as Astel­las Gene Ther­a­pies. Holles, hav­ing suc­cess­ful­ly steered both ef­forts, de­part­ed.

Still, ques­tions about pre­cise­ly what led to the deaths of the 3 boys still linger. Tri­al in­ves­ti­ga­tors re­leased key de­tails about the case last Au­gust and De­cem­ber, point­ing to a bi­o­log­i­cal land­mine that Au­dentes could not have seen com­ing — a mo­ment of pro­found med­ical mis­for­tune. In an emerg­ing field that’s promised cures for dev­as­tat­ing dis­eases but al­so seen its share of safe­ty set­backs, the cas­es pro­vid­ed a cau­tion­ary tale.

Au­dentes “con­tributed in a pos­i­tive way by giv­ing a painful but im­por­tant ex­am­ple for oth­ers to look at and learn from,” Ter­ry Flotte, dean of the UMass School of Med­i­cine and ed­i­tor of the jour­nal Hu­man Gene Ther­a­py, told me. “I can’t see any­thing they did wrong.”

Yet some re­searchers say they’re still wait­ing on Astel­las to re­lease more da­ta. The com­pa­ny has yet to pub­lish a full pa­per de­tail­ing what hap­pened, nor have they in­di­cat­ed that they will. In the mean­time, it re­mains un­clear what trig­gered the events and how to pre­vent them in the fu­ture.

“Since Au­dentes was the first one and we don’t have ad­di­tion­al in­for­ma­tion, we’re kind of in a hold­ing pat­tern, fly­ing around, wait­ing to fig­ure out how to land our ve­hi­cles,” said Jude Samul­s­ki, pro­fes­sor of phar­ma­col­o­gy at UNC’s Gene Ther­a­py Cen­ter and CSO of the gene ther­a­py biotech AskBio, now a sub­sidiary of Bay­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA